source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-12 16:33:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #EARNINGS--UNITED STATES STEEL CORPORATION (NYSE: X) TODAY PROVIDED FIRST QUARTER 2021 GUIDANCE. FIRST QUARTER 2021 ADJUSTED EBITDA IS EXPECTED TO BE APPROXIMATELY $540 MILLION AND EXCLUDES IMPACTS RELATED TO ACQUIRING THE REMAINING STAKE IN BIG RIVER STEEL. FIRST QUARTER 2021 ADJUSTED NET INCOME IS EXPECTED TO BE APPROXIMATELY $160 MILLION AND EXCLUDES IMPACTS RELATED TO ACQUIRING THE REMAINING STAKE IN BIG RIVER STEEL AS WELL AS IMPACTS FROM NON-RECURRING REFINANCING COSTS R
|
UNITED STATES STEEL CORPORATION PROVIDES FIRST QUARTER 2021 GUIDANCE
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-04 08:00:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X--UNITED STATES STEEL CORPORATION (NYSE: X) TODAY ANNOUNCED THE ACQUISITION OF THE FLAT ROLLED SHEET PATENTS AND TRADEMARKS OF THE NANOSTEEL COMPANY, INC. AS PART OF U. S. STEEL'S ONGOING COMMITMENT TO OFFER CUSTOMERS THE WORLD'S BEST SELECTION OF ADVANCED HIGH-STRENGTH STEELS, WHICH NOW INCLUDES THE MOST FORMABLE HIGH-STRENGTH STEEL AVAILABLE ANYWHERE. THE NANOSTEEL COMPANY DESIGNED AND DEVELOPED PATENTED PROPRIETARY ALLOYS WHICH DERIVE EXCEPTIONAL MECHANICAL PROPERT
|
U. S. STEEL SECURES NANOSTEEL® PATENTS TO EXPAND CAPABILITIES OF WORLD CLASS ADVANCED HIGH-STRENGTH STEEL OFFERINGS
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-17 07:58:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #USSTEEL--UNITED STATES STEEL CORPORATION (NYSE: X) (THE “COMPANY” OR “U. S. STEEL”) ANNOUNCED TODAY THAT, IN CONNECTION WITH ITS RECENTLY COMPLETED OFFERING OF 42,000,000 SHARES OF COMMON STOCK AT A PRICE TO THE PUBLIC OF $16.3733 PER SHARE, THE UNDERWRITER HAS EXERCISED IN FULL ITS OPTION TO PURCHASE 6,300,000 ADDITIONAL SHARES OF COMMON STOCK (THE "ADDITIONAL SHARES"). U. S. STEEL WILL RECEIVE ADDITIONAL NET PROCEEDS OF APPROXIMATELY $103.2 MILLION, AFTER DEDUCTING EXPENSE
|
UNITED STATES STEEL CORPORATION ANNOUNCES EXERCISE IN FULL OF UNDERWRITER'S OPTION TO PURCHASE ADDITIONAL COMMON SHARES
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-16 10:00:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #DIVIDEND--U. S. STEEL ANNOUNCED THAT IT HAS JOINED THE VALUABLE 500.
|
U. S. STEEL COMMITS TO DISABILITY INCLUSION BY JOINING THE VALUABLE 500
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-12 10:52:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #DIVIDEND--U. S. STEEL EARNED THE HIGHEST POSSIBLE RATING ON THE HUMAN RIGHTS CAMPAIGN FOUNDATION'S 2021 CORPORATE EQUALITY INDEX (CEI).
|
UNITED STATES STEEL CORPORATION EARNS HIGHEST RATING ON CORPORATE EQUALITY INDEX
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-08 17:13:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #USSTEEL--UNITED STATES STEEL CORPORATION (NYSE: X) (THE “COMPANY” OR “U. S. STEEL”) TODAY ANNOUNCED THE PRICING OF ITS UPSIZED $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF 6.875% SENIOR NOTES DUE 2029 (THE “NOTES”). THE SIZE OF THE OFFERING WAS UPSIZED FROM $500 MILLION TO $750 MILLION AGGREGATE PRINCIPAL AMOUNT OF NOTES. THE NOTES WILL BE ISSUED AT A PRICE EQUAL TO 100% OF THEIR FACE VALUE. THE NOTES WILL PAY INTEREST SEMI-ANNUALLY IN ARREARS ON MARCH 1 AND SEPTEMBER 1 OF EAC
|
UNITED STATES STEEL CORPORATION ANNOUNCES PRICING OF UPSIZED SENIOR NOTES OFFERING
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-08 07:41:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #USSTEEL--UNITED STATES STEEL CORPORATION (NYSE: X) (THE “COMPANY” OR “U. S. STEEL”) TODAY ANNOUNCED ITS INTENTION TO OFFER, SUBJECT TO MARKET AND OTHER CONDITIONS, $500 MILLION AGGREGATE PRINCIPAL AMOUNT OF SENIOR NOTES DUE 2029 (THE “NOTES”). ON FEBRUARY 2, 2021, U. S. STEEL ISSUED A NOTICE OF REDEMPTION TO REDEEM 35% OR APPROXIMATELY $370 MILLION AGGREGATE PRINCIPAL AMOUNT OUTSTANDING OF ITS 12.000% SENIOR SECURED NOTES DUE 2025 (THE “2025 SENIOR SECURED NOTES”). U. S. STE
|
UNITED STATES STEEL CORPORATION ANNOUNCES SENIOR NOTES OFFERING
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-02 22:27:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #USSTEEL--UNITED STATES STEEL CORPORATION (NYSE: X) (THE “COMPANY” OR “U. S. STEEL”) ANNOUNCED TODAY THE PRICING OF ITS UPSIZED UNDERWRITTEN PUBLIC OFFERING OF 42,000,000 SHARES OF COMMON STOCK, FOR GROSS PROCEEDS OF APPROXIMATELY $699 MILLION. THE SIZE OF THE OFFERING WAS UPSIZED FROM 40,000,000 SHARES TO 42,000,000 SHARES. THE COMPANY HAS GRANTED THE UNDERWRITER A 30-DAY OPTION TO PURCHASE UP TO 6,300,000 ADDITIONAL SHARES OF COMMON STOCK FROM THE COMPANY. THE OFFERING IS E
|
UNITED STATES STEEL CORPORATION ANNOUNCES PRICING OF UPSIZED COMMON STOCK OFFERING
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-02 16:24:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #USSTEEL--UNITED STATES STEEL CORPORATION (NYSE: X) (THE “COMPANY” OR “U. S. STEEL”) ANNOUNCED TODAY THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF 40,000,000 SHARES OF COMMON STOCK. U. S. STEEL INTENDS TO GRANT THE UNDERWRITER A 30-DAY OPTION TO PURCHASE UP TO 6,000,000 ADDITIONAL SHARES OF COMMON STOCK FROM THE COMPANY. U. S. STEEL INTENDS TO USE THE NET PROCEEDS FROM THE OFFERING TO REDEEM 35% OF ITS OUTSTANDING 2025 SENIOR SECURED NOTES AND FOR GENERAL CORPORATE
|
UNITED STATES STEEL CORPORATION ANNOUNCES COMMON STOCK OFFERING
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-28 17:15:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #DIVIDEND--UNITED STATES STEEL CORPORATION (NYSE: X) (“U. S. STEEL”) ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS DECLARED A DIVIDEND OF $0.01 PER SHARE OF U. S. STEEL COMMON STOCK. THE DIVIDEND IS PAYABLE ON TUESDAY, MARCH 9, 2021 TO STOCKHOLDERS OF RECORD AT THE CLOSE OF BUSINESS ON MONDAY, FEBRUARY 8, 2021. FOUNDED IN 1901, THE UNITED STATES STEEL CORPORATION IS A FORTUNE 250 COMPANY AND LEADING INTEGRATED STEEL PRODUCER. WITH EXTENSIVE IRON ORE PRODUCTION AND AN ANNUAL RAW
|
UNITED STATES STEEL CORPORATION DECLARES DIVIDEND
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-28 17:09:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #EARNINGS--UNITED STATES STEEL CORPORATION (NYSE: X) REPORTED FOURTH QUARTER 2020 NET EARNINGS OF $49 MILLION, OR $0.22 PER DILUTED SHARE. ADJUSTED NET LOSS WAS $60 MILLION, OR $0.27 PER DILUTED SHARE. THIS COMPARES TO FOURTH QUARTER 2019 NET LOSS OF $668 MILLION, OR $3.93 PER DILUTED SHARE. ADJUSTED NET LOSS FOR THE FOURTH QUARTER 2019 WAS $109 MILLION, OR $0.64 PER DILUTED SHARE. FULL-YEAR 2020 NET LOSS WAS $1,165 MILLION, OR $5.92 PER DILUTED SHARE. ADJUSTED NET LOSS WAS $9
|
UNITED STATES STEEL CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2020 RESULTS
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-27 11:08:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #DIVIDEND--TODAY, UNITED STATES STEEL CORPORATION (NYSE: X) ANNOUNCED THE APPOINTMENT OF SCOTT M. DORN AS INTERIM HEAD OF TUBULAR SOLUTIONS.
|
U. S. STEEL NAMES SCOTT DORN INTERIM HEAD OF TUBULAR SOLUTIONS
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-15 14:30:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #DIVIDEND--UNITED STATES STEEL CORPORATION (NYSE: X) (“U. S. STEEL”) ANNOUNCED TODAY IT CLOSED ITS ACQUISITION OF THE REMAINING EQUITY OF BIG RIVER STEEL (“BIG RIVER STEEL”) FOR APPROXIMATELY $774 MILLION FROM CASH ON HAND. THE TRANSACTION MET CUSTOMARY CLOSING CONDITIONS, INCLUDING ANTITRUST APPROVAL FROM THE UNITED STATES DEPARTMENT OF JUSTICE. “WE ARE CREATING THE FIRST ‘BEST OF BOTH' INTEGRATED AND MINI MILL STEEL COMPANY. TAKING A PAGE FROM THE BIG RIVER STEEL PLAYBOOK, W
|
UNITED STATES STEEL CORPORATION COMPLETES BIG RIVER STEEL ACQUISITION
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-23 18:05:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #DIVIDEND--UNITED STATES STEEL CORPORATION (NYSE: X) TODAY ANNOUNCED IT HAS CLOSED ON THE SALE OF ITS NON-CORE REAL ESTATE ASSET, THE KEYSTONE INDUSTRIAL PORT COMPLEX (KIPC), IN FAIRLESS HILLS, PENNSYLVANIA. UNDER THE TERMS OF THE SALE, THE COMPANY RECEIVED APPROXIMATELY $160 MILLION IN CASH. “THIS NON-CORE ASSET SALE DELIVERS ON OUR STRATEGIC COMMITMENT TO EXTRACT INCREMENTAL VALUE FROM OUR ATTRACTIVE PORTFOLIO OF REAL ESTATE ASSETS,” COMMENTED U. S. STEEL PRESIDENT AND CHIEF
|
UNITED STATES STEEL CORPORATION SELLS $160 MILLION KEYSTONE INDUSTRIAL PORT COMPLEX
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-17 16:20:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #DIVIDEND--U. S. STEEL TODAY PROVIDED FOURTH QUARTER 2020 GUIDANCE.
|
UNITED STATES STEEL CORPORATION PROVIDES FOURTH QUARTER 2020 GUIDANCE
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-08 06:49:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X #DIVIDEND--UNITED STATES STEEL CORPORATION ANNOUNCED TODAY IT HAS EXERCISED ITS CALL OPTION TO ACQUIRE THE REMAINING EQUITY OF BIG RIVER STEEL.
|
UNITED STATES STEEL CORPORATION TO ACQUIRE REMAINING EQUITY OF BIG RIVER STEEL
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-24 16:17:00
| null |
PITTSBURGH--(BUSINESS WIRE)---- $X--UNITED STATES STEEL CORPORATION (NYSE: X) TODAY ANNOUNCED THE CLOSING OF $63.4 MILLION OF ENVIRONMENTAL IMPROVEMENT REVENUE BONDS WITH A GREEN BOND DESIGNATION. THE COMPANY WILL USE PROCEEDS FROM THE GREEN BONDS TO PARTIALLY FUND WORK RELATED TO ITS NEW ENVIRONMENTALLY PREFERRED, LOW-EMISSION ELECTRIC ARC FURNACE AT U. S. STEEL'S FAIRFIELD WORKS. “OUR FIRST GREEN BOND IS AN IMPORTANT STEP FORWARD FOR U. S. STEEL IN OUR DRIVE TOWARD MORE SUSTAINABLE PRACTICES,” SAID
|
U. S. STEEL CLOSES ON GREEN BONDS TO FINANCE LOW-EMISSION, LOW-CARBON ELECTRIC ARC FURNACE IN ALABAMA
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-09-18 11:30:00
| null |
ORATION PROVIDES THIRD QUARTER 2020 GUIDANCE.SEES Q3 2020 ADJUSTED LOSS PER SHARE ABOUT $1.45.Q3 2020 ADJUSTED EBITDA IS EXPECTED TO BE APPROXIMATELY $100 MILLION LOSS.IMPROVING MARKET CONDITIONS EXPERIENCED IN JUNE AND JULY HAVE ACCELERATED THROUGH AUGUST AND SEPTEMBER.HAVE GROWN CONFIDENT IN RECOVERY THAT IS UNDERWAY IN NORTH AMERICA AND EUROPE.BY END OF QUARTER, PLAN TO REPAY APPROXIMATELY $900 MILLION OF U.S. ABL.EXPECT FLAT-ROLLED SEGMENT RESULTS TO BE NEGATIVE IN Q3.RESPONDED TO IMPROVING ORDER BOOK BY RESTARTING THREE BLAST FURNACES THAT WERE TEMPORARILY IDLED EARLIER THIS YEAR.EXPECT TWO BLAST FURNACES TO REMAIN TEMPORARILY IDLED THROUGH YEAR-END.IN EUROPE, PACE OF MARKET IMPROVEMENT HAS ALSO EXCEEDED EXPECTATIONS..IN TUBULAR, MARKET CONDITIONS APPEAR TO HAVE BOTTOMED, BUT CATALYSTS FOR IMPROVEMENT ARE LIMITED..Q3 EARNINGS PER SHARE VIEW $-1.53 -- REFINITIV IBES DATA.
|
UNITED STATES STEEL SEES Q3 2020 ADJUSTED LOSS PER SHARE ABOUT $1.45
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-07-30 18:30:00
| null |
ORATION REPORTS SECOND QUARTER 2020 RESULTS.Q2 ADJUSTED LOSS PER SHARE $2.67.Q2 LOSS PER SHARE $3.36.Q2 EARNINGS PER SHARE ESTIMATE $-2.82 -- REFINITIV IBES DATA.QTRLY NET SALES $2,091 MILLION VERSUS $3,545 MILLION.Q2 REVENUE VIEW $1.84 BILLION -- REFINITIV IBES DATA.Q2 PERFORMANCE WAS IMPACTED BY COVID-19.
|
UNITED STATES STEEL Q2 LOSS PER SHARE $3.36
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-18 00:30:00
| null |
ORATION ANNOUNCES PRICING OF COMMON STOCK OFFERING.SAYS OFFERING 50.0 MILLION COMMON SHARES.PUBLIC OFFERING OF 50,000,000 SHARES OF COMMON STOCK, FOR GROSS PROCEEDS OF APPROXIMATELY $429 MILLION.
|
UNITED STATES STEEL SAYS OFFERING 50 MLN COMMON SHARES, FOR GROSS PROCEEDS OF ABOUT $429 MLN
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-17 19:30:00
| null |
U.S. STEEL, UNDER RISK FACTORS, SAYS INTEND TO PAY QTRLY DIVIDEND; BUT MAY NOT DECLARE, PAY DIVIDENDS IN FUTURE AT PRIOR RATE OR AT ALL - SEC FILING.
|
U.S. STEEL INTEND TO PAY QTRLY DIVIDEND BUT MAY NOT DECLARE, PAY DIVIDENDS IN FUTURE AT PRIOR RATE OR AT ALL - SEC FILING
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-17 18:30:00
| null |
ORATION ANNOUNCES COMMON STOCK OFFERING.SAYS OFFERING 50.0 MILLION COMMON SHARES.INTENDS TO USE NET PROCEEDS FROM OFFERING TO STRENGTHEN BALANCE SHEET, INCREASE LIQUIDITY.
|
UNITED STATES STEEL ANNOUNCES COMMON STOCK OFFERING
|
X
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-22 16:05:00
| null |
SUCCESSFULLY COMPLETED PHASE 1 OF U.S. COMMERCIAL LAUNCH, WITH MULTIPLE HOSPITALS CONTRACTED, AND HAVE INITIATED PHASE 2 OF LAUNCH FOR LUNGFIT® PH FOR THE TREATMENT OF TERM AND NEAR-TERM NEONATES WITH HYPOXIC RESPIRATORY FAILURE
|
BEYOND AIR® REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR-END 2023
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-15 16:10:00
| null |
FUNDING TO SUPPORT THE COMMERCIALIZATION OF LUNGFIT® PH AND ADVANCE THE CLINICAL DEVELOPMENT OF HIGH CONCENTRATION NITRIC OXIDE TREATMENT USING BEYOND AIR'S REVOLUTIONARY LUNGFIT PLATFORM TECHNOLOGY FUNDING TO SUPPORT THE COMMERCIALIZATION OF LUNGFIT® PH AND ADVANCE THE CLINICAL DEVELOPMENT OF HIGH CONCENTRATION NITRIC OXIDE TREATMENT USING BEYOND AIR'S REVOLUTIONARY LUNGFIT PLATFORM TECHNOLOGY
|
BEYOND AIR® SECURES UP TO $40 MILLION DEBT FINANCING
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-19 09:00:00
| null |
SINGLE AND REPEAT DOSING OF UNO IMPROVES OUTCOMES COMPARED TO CHECKPOINT INHIBITOR MONOTHERAPY IN THE AGGRESSIVE 4T1 BREAST CANCER MODEL
|
BEYOND CANCER™ PRESENTS POSITIVE PRECLINICAL DATA FOR ULTRA-HIGH CONCENTRATION NITRIC OXIDE (UNO) THERAPY IN SOLID TUMORS DURING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) 2023 ANNUAL MEETING
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-23 16:05:00
| null |
DR. MYERS BRINGS EXTENSIVE EXECUTIVE EXPERIENCE LEADING THE DEVELOPMENT OF CLINICAL PROGRAMS THROUGH US AND GLOBAL REGULATORY APPROVAL DR. MYERS BRINGS EXTENSIVE EXECUTIVE EXPERIENCE LEADING THE DEVELOPMENT OF CLINICAL PROGRAMS THROUGH US AND GLOBAL REGULATORY APPROVAL
|
BEYOND AIR® APPOINTS JEFF MYERS, M.D. PH.D. AS CHIEF MEDICAL OFFICER
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-02-09 16:05:00
| null |
U.S. COMMERCIAL LAUNCH CONTINUES FOR LUNGFIT® PH FOR THE TREATMENT OF TERM AND NEAR-TERM NEONATES WITH HYPOXIC RESPIRATORY FAILURE
|
BEYOND AIR® REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF FISCAL YEAR 2023
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-30 07:00:00
| null |
DR. CHOY BRINGS MORE THAN 20+ YEARS OF PHARMACEUTICAL AND BIOTECHNOLOGY OPERATING EXPERIENCE TO BEYOND CANCER DR. CHOY BRINGS MORE THAN 20+ YEARS OF PHARMACEUTICAL AND BIOTECHNOLOGY OPERATING EXPERIENCE TO BEYOND CANCER
|
BEYOND CANCER® APPOINTS GAVIN CHOY, PHARMD AS CHIEF OPERATING OFFICER
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-24 16:05:00
| null |
DR. DIRBAS, ASSOCIATE PROFESSOR OF SURGERY AT THE STANFORD SCHOOL OF MEDICINE WILL CHAIR THE SCIENTIFIC ADVISORY BOARD (SAB)
|
BEYOND CANCER® ANNOUNCES SPONSORED RESEARCH AGREEMENT WITH STANFORD AND APPOINTMENT OF FREDERICK M. DIRBAS, MD AND MARK D.
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-13 09:25:00
| null |
DATA DESCRIBE A POTENT SYSTEMIC IMMUNE RESPONSE RESULTING IN A SIGNIFICANT REDUCTION IN CHALLENGE TUMORS AND IMPROVEMENT IN SURVIVAL FOR UNO TREATED MICE DATA DESCRIBE A POTENT SYSTEMIC IMMUNE RESPONSE RESULTING IN A SIGNIFICANT REDUCTION IN CHALLENGE TUMORS AND IMPROVEMENT IN SURVIVAL FOR UNO TREATED MICE
|
BEYOND CANCER® PUBLISHES PRE-CLINICAL DATA IN CANCER CELL INTERNATIONAL DEMONSTRATING ITS TUMOR ABLATION METHOD UTILIZING ULTRA-HIGH CONCENTRATION NITRIC OXIDE (UNO) INDUCED A SYSTEMIC RESPONSE THAT PREVENTS METASTASES
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-08 16:05:00
| null |
COMMERCIAL LAUNCH UNDERWAY FOR LUNGFIT® PH FOR THE TREATMENT OF TERM AND NEAR-TERM NEONATES WITH HYPOXIC RESPIRATORY FAILURE, WHICH RECEIVED FDA APPROVAL ON JUNE 28, 2022
|
BEYOND AIR® REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL YEAR 2023
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-24 07:30:00
| null |
-- DURATION OF OXYGEN SUPPORT WAS SIGNIFICANTLY SHORTER FOR SUBJECTS TREATED WITH INHALED NO
|
BEYOND AIR® ANNOUNCES POSITIVE DATA FOR INHALED NITRIC OXIDE (NO) TO TREAT COVID-19 WITH LUNGFIT® PRO IN A POSTER PRESENTATION AT IDWEEK 2022
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-17 16:05:00
| null |
-- DATA SHOW FAVORABLE SAFETY, TOLERABILITY, AND EFFICACY RESULTS -- -- ALL PATIENTS TITRATED TO 250 PPM NO WITH NO PATIENTS NEEDING TO REDUCE CONCENTRATION --
|
BEYOND AIR® ANNOUNCES POSITIVE DATA FROM AT-HOME PILOT STUDY IN PATIENTS WITH REFRACTORY NTM LUNG INFECTION TREATED WITH (NO) USING THE LUNGFIT® GO AT THE CHEST ANNUAL MEETING 2022
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-03 07:30:00
| null |
GARDEN CITY, N.Y., OCT. 03, 2022 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR), A MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INHALED NITRIC OXIDE (NO) FOR THE TREATMENT OF PATIENTS WITH RESPIRATORY CONDITIONS, INCLUDING SERIOUS LUNG INFECTIONS AND PULMONARY HYPERTENSION, AND, THROUGH ITS AFFILIATE BEYOND CANCER, ULTRA-HIGH CONCENTRATION NITRIC OXIDE (UNO) FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT THE ANNALS OF THE AMERICAN THORACIC SOCIETY PUBLISHED A DETAILED REVIEW OF THE COMPANY'S THIRD PILOT STUDY OF INHALED NO IN BRONCHIOLITIS PATIENTS. THE PUBLICATION OFFERS AN OVERVIEW OF THE STUDY DESIGN AND PREVIOUSLY ANNOUNCED RESULTS, AS WELL AS THE RATIONALE FOR CONDUCTING A PIVOTAL STUDY. THE MANUSCRIPT IN THE ANNALS OF THE AMERICAN THORACIC SOCIETY IS AVAILABLE AT (HTTPS://DOI.ORG/10.1513/ANNALSATS.202103-348OC).
|
BEYOND AIR® ANNOUNCES THAT ANNALS OF THE AMERICAN THORACIC SOCIETY PUBLISHED A REVIEW OF THE THIRD PILOT STUDY OF HIGH DOSE NITRIC OXIDE FOR BRONCHIOLITIS
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-23 08:00:00
| null |
GARDEN CITY, N.Y. AND HAMILTON, BERMUDA, AUG. 23, 2022 (GLOBE NEWSWIRE) -- BEYOND CANCER, LTD., AN AFFILIATE OF BEYOND AIR, INC. (NASDAQ: XAIR) THAT IS FOCUSED ON DEVELOPING ULTRA-HIGH CONCENTRATION NITRIC OXIDE (UNO) FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT THE FIRST PATIENT WAS TREATED IN A FIRST-IN-HUMAN PHASE 1 STUDY TO ASSESS THE SAFETY AND IMMUNE BIOMARKERS OF UNO THERAPY.
|
BEYOND AIR® AFFILIATE BEYOND CANCER™ DOSES INITIAL PATIENT IN FIRST-IN-HUMAN PHASE 1 STUDY OF ULTRA-HIGH CONCENTRATION NITRIC OXIDE THERAPY AT TEL AVIV SOURASKY MEDICAL CENTER (ICHILOV)
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-28 16:10:00
| null |
LUNGFIT® PH RECEIVED FDA APPROVAL FOR THE TREATMENT OF TERM AND NEAR-TERM NEONATES WITH HYPOXIC RESPIRATORY FAILURE ON JUNE 28, 2022 AND THE FIRST PHASE OF U.S. COMMERCIAL LAUNCH HAS BEGUN
|
BEYOND AIR® REPORTS FINANCIAL RESULTS FOR FOURTH FISCAL QUARTER AND YEAR-END 2022
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-28 16:05:00
| null |
FIRST AND ONLY NITRIC OXIDE GENERATOR AND DELIVERY SYSTEM INDICATED FOR THE TREATMENT OF TERM AND NEAR-TERM NEONATES WITH HYPOXIC RESPIRATORY FAILURE THAT USES AMBIENT AIR TO PROVIDE UNLIMITED, ON-DEMAND NITRIC OXIDE
|
BEYOND AIR'S LUNGFIT® PH RECEIVES FDA APPROVAL TO TREAT TERM AND NEAR-TERM NEONATES WITH HYPOXIC RESPIRATORY FAILURE
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-01 07:00:00
| null |
DR. MONSON IS A BOARD-CERTIFIED RADIATION ONCOLOGIST AND BRINGS OVER 25 YEARS OF CLINICAL ONCOLOGY EXPERIENCE TO BEYOND CANCER.
|
BEYOND CANCER™ ANNOUNCES THE APPOINTMENT OF JEDIDIAH MONSON, M.D. TO CHIEF MEDICAL OFFICER
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-17 07:00:00
| null |
MS. JONES BRINGS OVER 30 YEARS OF LIFE SCIENCE BASED FINANCIAL EXPERIENCE TO BEYOND CANCER MS. JONES BRINGS OVER 30 YEARS OF LIFE SCIENCE BASED FINANCIAL EXPERIENCE TO BEYOND CANCER
|
BEYOND CANCER, LTD. APPOINTS SUSAN HOWELL JONES, CPA AS CHIEF FINANCIAL OFFICER
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-25 16:05:00
| null |
GARDEN CITY, N.Y., APRIL 25, 2022 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR), A CLINICAL-STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INHALED NITRIC OXIDE (NO) FOR THE TREATMENT OF PATIENTS WITH RESPIRATORY CONDITIONS, INCLUDING SERIOUS LUNG INFECTIONS AND PULMONARY HYPERTENSION AND, THROUGH ITS AFFILIATE BEYOND CANCER, ULTRA-HIGH CONCENTRATION NITRIC OXIDE (UNO) FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED POSITIVE LONG-TERM SAFETY DATA FOR HIGH CONCENTRATION INHALED NO FOR THE TREATMENT OF BRONCHIOLITIS. THESE DATA WERE INCLUDED IN AN ORAL PRESENTATION AT THE PEDIATRIC ACADEMIC SOCIETIES 2022 MEETING (PAS 2022), WHICH IS BEING HELD APRIL 21-25 IN DENVER, COLORADO.
|
BEYOND AIR® REPORTS POSITIVE LONG-TERM SAFETY DATA FOR HIGH CONCENTRATION INHALED NITRIC OXIDE IN BRONCHIOLITIS AT THE PEDIATRIC ACADEMIC SOCIETIES MEETING 2022
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-25 07:00:00
| null |
INHALED NO TREATMENT IN PATIENTS HOSPITALIZED WITH COVID-19 AND OTHER COMMUNITY-ACQUIRED VIRAL PNEUMONIA WAS WELL TOLERATED OVERALL, AND SAFE, WITH IMPROVED EFFICACY PARAMETERS AS COMPARED TO STANDARD SUPPORTIVE TREATMENT
|
BEYOND AIR® PRESENTS POSITIVE SAFETY AND EFFICACY DATA FOR INHALED NITRIC OXIDE TO TREAT COVID-19 AT ECCMID 2022
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-18 07:00:00
| null |
GARDEN CITY, N.Y., APRIL 18, 2022 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR), A CLINICAL-STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INHALED NITRIC OXIDE (NO) FOR THE TREATMENT OF PATIENTS WITH RESPIRATORY CONDITIONS, INCLUDING SERIOUS LUNG INFECTIONS AND PULMONARY HYPERTENSION AND, THROUGH ITS AFFILIATE BEYOND CANCER, ULTRA-HIGH CONCENTRATION NITRIC OXIDE (UNO) FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT THE COMPANY IS SCHEDULED TO PRESENT NEW DATA AT THREE UPCOMING MEDICAL CONFERENCES.
|
BEYOND AIR® TO PARTICIPATE IN THREE UPCOMING MEDICAL CONFERENCES
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-11 07:00:00
| null |
DATA SUGGESTS ULTRA-HIGH CONCENTRATION GASEOUS NO (GNO) INDUCED BOTH INNATE AND ADAPTIVE IMMUNE CELL POPULATIONS, AND A DECLINE IN IMMUNE SUPPRESSOR CELLS, WHICH ARE INDICATIVE OF AN ANTI-TUMOR IMMUNE RESPONSE
|
BEYOND CANCER™ ANNOUNCES NEW PRECLINICAL DATA PRESENTED AT AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) SHOWING ULTRA-HIGH CONCENTRATION NITRIC OXIDE THERAPY ANTI-TUMOR EFFECT
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-02 08:00:00
| null |
GARDEN CITY, N.Y., NOV. 02, 2021 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR), A CLINICAL-STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INHALED NITRIC OXIDE (NO) FOR THE TREATMENT OF PATIENTS WITH RESPIRATORY CONDITIONS, INCLUDING SERIOUS LUNG INFECTIONS AND PULMONARY HYPERTENSION, AND GASEOUS NO (GNO) FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT STEVE LISI, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF BEYOND AIR, WILL PARTICIPATE IN THE PIPER SANDLER 33RD ANNUAL VIRTUAL HEALTHCARE CONFERENCE BEING HELD FROM NOVEMBER 30 – DECEMBER 2, 2021. BEYOND AIR WILL PROVIDE A PRE-RECORDED INVESTOR PRESENTATION AND WILL BE AVAILABLE FOR VIRTUAL ONE-ON-ONE MEETINGS DURING THE CONFERENCE.
|
BEYOND AIR® TO PARTICIPATE IN THE PIPER SANDLER 33RD ANNUAL VIRTUAL HEALTHCARE CONFERENCE
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-21 16:30:00
| null |
FDA INSPECTION OF FACILITIES IS ONGOING; US COMMERCIAL LAUNCH REMAINS ON TRACK FOR 4Q CY2021, PENDING FDA APPROVAL
|
BEYOND AIR® PROVIDES GLOBAL REGULATORY UPDATE FOR LUNGFIT® PH
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-14 07:30:00
| null |
GARDEN CITY, N.Y., SEPT. 14, 2021 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR), A CLINICAL-STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INHALED NITRIC OXIDE (NO) FOR THE TREATMENT OF PATIENTS WITH RESPIRATORY CONDITIONS, INCLUDING SERIOUS LUNG INFECTIONS AND PULMONARY HYPERTENSION, AND GASEOUS NO (GNO) FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT STEVE LISI, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF BEYOND AIR, IS SCHEDULED TO PRESENT AT THE OPPENHEIMER FALL HEALTHCARE LIFE SCIENCES & MEDTECH SUMMIT BEING HELD VIRTUALLY FROM SEPTEMBER 20TH TO 23RD.
|
BEYOND AIR® TO PRESENT AT THE OPPENHEIMER FALL HEALTHCARE LIFE SCIENCES & MEDTECH SUMMIT
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-20 16:15:00
| null |
GARDEN CITY, N.Y., AUG. 20, 2021 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR), A CLINICAL-STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INHALED NITRIC OXIDE (NO) FOR THE TREATMENT OF PATIENTS WITH RESPIRATORY CONDITIONS, INCLUDING SERIOUS LUNG INFECTIONS AND PULMONARY HYPERTENSION, AND GASEOUS NO (GNO) FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THE APPOINTMENT OF DOUGLAS LARSON AS CHIEF FINANCIAL OFFICER, SUCCEEDING DOUGLAS BECK EFFECTIVE SEPTEMBER 1, 2021. MR. BECK WILL REMAIN A CONSULTANT TO THE COMPANY AND IS EXPECTED TO WORK CLOSELY WITH MR. LARSON AND THE BEYOND AIR LEADERSHIP TEAM TO ENSURE A SEAMLESS TRANSITION OF CFO RESPONSIBILITIES.
|
BEYOND AIR® ANNOUNCES CFO TRANSITION
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-20 07:30:00
| null |
CALL SCHEDULED FOR TUESDAY, AUGUST 10TH AT 4:30 PM EASTERN TIME CALL SCHEDULED FOR TUESDAY, AUGUST 10TH AT 4:30 PM EASTERN TIME
|
BEYOND AIR® SCHEDULES FIRST FISCAL QUARTER 2022 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-08 16:14:00
| null |
GARDEN CITY, N.Y., JULY 08, 2021 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR), A CLINICAL-STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INHALED NITRIC OXIDE (NO) FOR THE TREATMENT OF PATIENTS WITH RESPIRATORY CONDITIONS, INCLUDING SERIOUS LUNG INFECTIONS AND PULMONARY HYPERTENSION, AND GASEOUS NO (GNO) FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT STEVE LISI, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF BEYOND AIR, IS SCHEDULED TO PARTICIPATE IN TWO UPCOMING VIRTUAL INVESTOR CONFERENCES IN JULY 2021.
|
BEYOND AIR® ANNOUNCES PARTICIPATION AT UPCOMING VIRTUAL INVESTOR CONFERENCES IN JULY 2021
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-10 16:05:00
| null |
SUBMITTED FIRST PREMARKET APPROVAL (PMA) APPLICATION IN THE COMPANY'S HISTORY TO FDA FOR LUNGFIT ® PH TO TREAT PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN); COMPANY PREPARING FOR COMMERCIAL LAUNCH IN THE FOURTH QUARTER OF CALENDAR YEAR 2021
|
BEYOND AIR® REPORTS FINANCIAL RESULTS FOR FOURTH FISCAL QUARTER AND YEAR-END 2021
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-26 07:30:00
| null |
GARDEN CITY, N.Y., MAY 26, 2021 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR), A CLINICAL-STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INHALED NITRIC OXIDE (NO) FOR THE TREATMENT OF PATIENTS WITH RESPIRATORY CONDITIONS, INCLUDING SERIOUS LUNG INFECTIONS AND PULMONARY HYPERTENSION, AND GASEOUS NO (GNO) FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED AN AGREEMENT WITH FORMER LUNGFIT® PH COMMERCIAL LICENSEE, CIRCASSIA GROUP PLC. UNDER THE TERMS OF THE AGREEMENT, BEYOND AIR RETAINS UNITED STATES AND CHINA COMMERCIALIZATION RIGHTS TO LUNGFIT® PH IN EXCHANGE FOR RETURNING UPFRONT AND MILESTONE PAYMENTS RECEIVED BY THE COMPANY IN 2019, ALONG WITH CAPPED FUTURE ROYALTY PAYMENTS. BEYOND AIR NOW HOLDS FULL GLOBAL RIGHTS TO LUNGFIT® PH.
|
BEYOND AIR® REACHES SETTLEMENT AGREEMENT WITH CIRCASSIA FOR LUNGFIT® PH
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-25 07:30:00
| null |
CALL SCHEDULED FOR THURSDAY, JUNE 10TH AT 4:30 PM EASTERN TIME CALL SCHEDULED FOR THURSDAY, JUNE 10TH AT 4:30 PM EASTERN TIME
|
BEYOND AIR® SCHEDULES FISCAL YEAR 2021 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-03 08:00:00
| null |
FORMER DIRECTOR OF HEALTHCARE PARTNERSHIPS AND EXTERNAL RELATIONS AT LINDE PLC BRINGS 26 YEARS OF EXPERIENCE TO BEYOND AIR FORMER DIRECTOR OF HEALTHCARE PARTNERSHIPS AND EXTERNAL RELATIONS AT LINDE PLC BRINGS 26 YEARS OF EXPERIENCE TO BEYOND AIR
|
BEYOND AIR® APPOINTS PETER SENIOR AS DIRECTOR OF BUSINESS DEVELOPMENT
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-14 08:00:00
| null |
GARDEN CITY, N.Y., APRIL 14, 2021 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR), A CLINICAL-STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INHALED NITRIC OXIDE (NO) FOR THE TREATMENT OF PATIENTS WITH RESPIRATORY CONDITIONS, INCLUDING SERIOUS LUNG INFECTIONS AND PULMONARY HYPERTENSION, AND GASEOUS NO (GNO) FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT STEVE LISI, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF BEYOND AIR, IS SCHEDULED TO PARTICIPATE IN TWO UPCOMING VIRTUAL INVESTOR CONFERENCES IN MAY 2021.
|
BEYOND AIR® ANNOUNCES PARTICIPATION AT UPCOMING VIRTUAL INVESTOR CONFERENCES IN MAY 2021
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-16 08:00:00
| null |
AWARD WILL HELP FUND THE DEVELOPMENT OF HIGH CONCENTRATION NITRIC OXIDE (NO) FOR NONTUBERCULOUS MYCOBACTERIA (NTM) PULMONARY DISEASE, WHICH DISPROPORTIONATELY AFFECTS CYSTIC FIBROSIS (CF) PATIENTS
|
BEYOND AIR® RECEIVES GRANT FOR UP TO $2.17 MILLION FROM THE CYSTIC FIBROSIS FOUNDATION TO ADVANCE THE CLINICAL DEVELOPMENT OF INHALED NITRIC OXIDE TO TREAT NONTUBERCULOUS MYCOBACTERIA PULMONARY DISEASE
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-09 16:05:00
| null |
U.S. FDA REVIEWING PREMARKET APPROVAL (PMA) SUBMISSION FOR LUNGFITTM PH TO TREAT PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN), AS COMPANY PREPARES FOR COMMERCIALIZATION
|
BEYOND AIR® REPORTS FINANCIAL RESULTS FOR THIRD QUARTER OF FISCAL YEAR 2021 AND PROVIDES BUSINESS UPDATE
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-19 08:00:00
| null |
GARDEN CITY, N.Y., NOV. 19, 2020 (GLOBE NEWSWIRE) -- BEYOND AIR, INC. (NASDAQ: XAIR), A CLINICAL-STAGE MEDICAL DEVICE AND BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INHALED NITRIC OXIDE (NO) FOR THE TREATMENT OF PATIENTS WITH RESPIRATORY CONDITIONS, INCLUDING SERIOUS LUNG INFECTIONS AND PULMONARY HYPERTENSION, AND GASEOUS NO (GNO) FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT STEVE LISI, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF BEYOND AIR, WILL PARTICIPATE IN THE 32ND ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE BEING HELD VIRTUALLY FROM DECEMBER 1-3, 2020. BEYOND AIR WILL PROVIDE A PRE-RECORDED INVESTOR PRESENTATION AND WILL BE AVAILABLE FOR VIRTUAL ONE-ON-ONE MEETINGS DURING THE CONFERENCE.
|
BEYOND AIR® TO PARTICIPATE IN THE 32ND ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE FROM DECEMBER 1-3, 2020
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-11 07:30:00
| null |
POTENTIAL TO REVOLUTIONIZE NITRIC OXIDE THERAPY BY ELIMINATING NEED FOR CUMBERSOME CYLINDERS CREATING IM PROVED ECONOMICS AND SAFETY IN HOSPITAL SETTING
|
BEYOND AIR® SUBMITS PREMARKET APPROVAL APPLICATION TO FDA FOR LUNGFIT™ PH TO TREAT PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-22 19:30:00
| null |
BEYOND AIR REPORTS FINANCIAL RESULTS FOR FISCAL FOURTH QUARTER AND YEAR-END 2020.Q4 LOSS PER SHARE $0.36.Q4 EARNINGS PER SHARE ESTIMATE $-0.39 -- REFINITIV IBES DATA.BEYOND AIR - PMA FOR LUNGFIT PH TO TREAT PERSISTENT PULMONARY HYPERTENSION OF NEWBORN EXPECTED TO BE SUBMITTED TO FDA IN H2 2020.BEYOND AIR - ENROLLED FIRST PATIENT IN U.S. COVID-19 STUDY USING LUNGFIT SYSTEM.BEYOND AIR - LUNGFIT HOME NONTUBERCULOUS MYCOBACTERIA (NTM) LUNG INFECTION PILOT STUDY EXPECTED TO START BY END OF 2020.BEYOND AIR - AS OF MARCH 31, HAD CASH, EQUIVALENTS, RESTRICTED CASH OF $25.5 MILLION.
|
BEYOND AIR REPORTS Q4 LOSS PER SHARE $0.36
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-16 10:30:00
| null |
BEYOND AIR SUBMITS INVESTIGATIONAL DEVICE EXEMPTION (IDE) TO THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF COVID-19 PATIENTS.BEYOND AIR INC - LUNGFIT BRO SYSTEM TO BE USED IN PROPOSED STUDY TO TREAT COVID-19 PATIENTS.BEYOND AIR INC - GRANT APPLICATIONS HAVE BEEN SUBMITTED TO BIOMEDICAL ADVANCE RESEARCH AND DEVELOPMENT AUTHORITY (BARDA), A DIVISION OF HEALTH AND HHS.BEYOND AIR - SECOND TRIAL DESIGN BEING VETTED TO INVESTIGATE USE IN PATIENTS EXPOSED TO SEVERE ACUTE RESPIRATORY SYNDROME 2 (SARS-COV-2), BUT NOT INFECTED.
|
BEYOND AIR SUBMITS INVESTIGATIONAL DEVICE EXEMPTION TO THE UNITED STATES FDA FOR THE TREATMENT OF COVID-19 PATIENTS
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-13 19:30:00
| null |
CHARLES MOSSERI MARLIO REPORTS 9.8% PASSIVE STAKE IN BEYOND AIR INC AS OF MARCH 9, 2020 - SEC FILING.
|
CHARLES MOSSERI MARLIO REPORTS 9.8% PASSIVE STAKE IN BEYOND AIR
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-09 20:30:00
| null |
BEYOND AIR ANNOUNCES PROPOSED PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT.BEYOND AIR - ANNOUNCED THAT IT INTENDS TO OFFER AND SELL SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.BEYOND AIR - EXPECTS TO SELL TO CERTAIN INVESTORS IN A PRIVATE PLACEMENT, A NUMBER OF SHARES EQUAL TO PURCHASE PRICE OF UP TO $2.0 MILLION.
|
BEYOND AIR ANNOUNCES PROPOSED PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-25 16:30:00
| null |
BEYOND AIR - SIGNS AGREEMENT WITH MESA SPECIALTY GASES & EQUIPMENT FOR NITRIC OXIDE AND NITROGEN DIOXIDE CALIBRATION GAS SUPPLY.
|
BEYOND AIR SAYS SIGNS AGREEMENT WITH MESA SPECIALTY GASES & EQUIPMENT FOR NITRIC OXIDE AND NITROGEN DIOXIDE CALIBRATION GAS SUPPLY
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-24 22:30:00
| null |
BEYOND AIR, INC. ANNOUNCED AN EXCLUSIVE FIVE-YEAR GLOBAL SUPPLY AGREEMENT FOR NO AND NO2 (NITROGEN DIOXIDE) CALIBRATION GAS WITH MESA SPECIALTY GASES & EQUIPMENT. FIVE YEAR TERM BEGINS ON THE EARLIER OF FDA APPROVAL FOR THE LUNGFIT PH SYSTEM OR DECEMBER 31, 2020. BEYOND AIR WILL BE RESPONSIBLE FOR THE INITIAL AND FUTURE COSTS FOR ADJUSTMENTS TO MESA FACILITIES TO MEET CAPACITY REQUIREMENTS (ESTIMATED TO BE LESS THAN $100,000). BEYOND AIR HAS THE OPTION TO HAVE MESA DESIGN AND OPERATE A CALIBRATION GAS MANUFACTURING FACILITY DEDICATED TO BEYOND AIR. DEAL IS EXCLUSIVE ON A GLOBAL BASIS TO BOTH COMPANIES.
|
BEYOND AIR, INC. SIGNS AGREEMENT WITH MESA SPECIALTY GASES & EQUIPMENT FOR NITRIC OXIDE AND NITROGEN DIOXIDE CALIBRATION GAS SUPPLY
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-06 21:30:00
| null |
BEYOND AIR™ REPORTS FINANCIAL RESULTS FOR FISCAL SECOND QUARTER 2020.Q2 LOSS PER SHARE $0.38.Q2 EARNINGS PER SHARE ESTIMATE $-0.30 -- REFINITIV IBES DATA.ENDED QUARTER WITH $9.8 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES.
|
BEYOND AIR REPORTS FINANCIAL RESULTS FOR FISCAL SECOND QUARTER 2020
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-05 22:30:00
| null |
BEYOND AIR, INC. ANNOUNCED EARNINGS RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2019. FOR THE SECOND QUARTER, THE COMPANY ANNOUNCED OPERATING LOSS WAS USD 4.269 MILLION COMPARED TO USD 2.413 MILLION A YEAR AGO. NET LOSS WAS USD 4.097 MILLION COMPARED TO USD 2.389 MILLION A YEAR AGO. BASIC LOSS PER SHARE WAS USD 0.38 COMPARED TO USD 0.28 A YEAR AGO. FOR THE HALF YEAR, OPERATING LOSS WAS USD 8.147 MILLION COMPARED TO USD 4.169 MILLION A YEAR AGO. NET LOSS WAS USD 10.278 MILLION COMPARED TO USD 4.107 MILLION A YEAR AGO. BASIC LOSS PER SHARE WAS USD 1.03 COMPARED TO USD 0.49 A YEAR AGO.
|
BEYOND AIR, INC. REPORTS EARNINGS RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2019
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-23 22:30:00
| null |
BEYOND AIR, INC., Q2 2020 EARNINGS CALL, NOV 06, 2019
|
BEYOND AIR, INC., Q2 2020 EARNINGS CALL, NOV 06, 2019
|
XAIR
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-21 16:05:00
| null |
WESTBURY, N.Y., DEC. 21, 2020 /PRNEWSWIRE/ -- EXANTAS CAPITAL CORP. (NYSE:XAN) (THE "COMPANY") ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS DECLARED A CASH DIVIDEND ON ITS 8.625% FIXED-TO-FLOATING SERIES C CUMULATIVE REDEEMABLE PREFERRED STOCK FOR THE PERIOD FROM OCTOBER 31, 2020 THROUGH...
|
EXANTAS CAPITAL CORP. DECLARES QUARTERLY CASH DIVIDENDS FOR SERIES C PREFERRED STOCK
|
XAN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-08-03 09:30:00
| null |
EXANTAS CAPITAL CORP. ANNOUNCES ACQUISITION OF MANAGEMENT CONTRACT FROM C-III CAPITAL PARTNERS BY ACRES CAPITAL CORP. AND $375 MILLION FINANCING FROM MASSMUTUAL AND OAKTREE CAPITAL MANAGEMENT.EXANTAS CAPITAL CORP - IN CONNECTION WITH TRANSACTIONS, ACRES AND COMPANY ENTERED INTO AN AMENDED AND RESTATED MANAGEMENT AGREEMENT.EXANTAS CAPITAL CORP - EXPECTS NEW FINANCING TO PROVIDE AMPLE LIQUIDITY TO MEET CURRENT FINANCING REQUIREMENTS, AND FOR NEW INVESTMENTS.EXANTAS CAPITAL CORP - NEW MANAGER, ACRES, HAS ASSUMED MANAGEMENT RESPONSIBILITY EFFECTIVE IMMEDIATELY.EXANTAS CAPITAL - ANDREW FENTRESS & MARK FOGEL, CO-FOUNDERS OF ACRES, WILL SERVE AS CHAIRMAN OF BOARD, & AS PRESIDENT, CEO OF EXANTAS, RESPECTIVELY.EXANTAS CAPITAL CORP - ENTERED INTO A $250 MILLION SEVEN-YEAR SENIOR SECURED FINANCING FACILITY WITH MASSMUTUAL.EXANTAS CAPITAL CORP - ACRES HAS ADDED 18 PROFESSIONALS FROM FORMER C-III TEAM TO ITS STAFF, INCLUDING DAVID BRYANT, CURRENT CFO OF EXANTAS.
|
EXANTAS ANNOUNCES ACQUISITION OF MANAGEMENT CONTRACT FROM C-III CAPITAL PARTNERS BY ACRES CAPITAL
|
XAN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-05-08 01:30:00
| null |
REPORTS RESULTS FOR THREE MONTHS ENDED MARCH 31, 2020.QUARTERLY GAAP LOSS PER SHARE $6.30.QUARTERLY ADJUSTED CORE EARNINGS PER SHARE $0.23.QTRLY CORE LOSS $5.47 PER COMMON SHARE-DILUTED.
|
EXANTAS CAPITAL CORP REPORTS QTRLY GAAP LOSS PER SHARE OF $6.30
|
XAN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-25 11:30:00
| null |
EXANTAS CAPITAL CORP - CO AND ITS SUBSIDIARIES HAVE RECEIVED MARGIN CALLS FROM CMBS REPO FINANCING COUNTERPARTIES.EXANTAS CAPITAL - AS OF CLOSE OF BUSINESS ON MARCH 23, CO DID NOT MEET ALL OF ITS MARGIN CALLS.EXANTAS CAPITAL - REQUESTED CMBS REPO FINANCING COUNTERPARTIES TO FORBEAR FROM EXERCISING RIGHTS UNDER APPLICABLE AGREEMENTS TO ALLOW CO TO EVALUATE OPTIONS.EXANTAS CAPITAL - RESCINDED PREVIOUSLY ANNOUNCED CASH DIVIDEND OF $0.275 PER COMMON SHARE FOR SHAREHOLDERS OF RECORD ON MAR 31.
|
EXANTAS CAPITAL AND ITS SUBSIDIARIES HAVE RECEIVED MARGIN CALLS FROM CMBS REPO FINANCING COUNTERPARTIES
|
XAN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-04 02:30:00
| null |
REPORTS RESULTS FOR THREE MONTHS AND YEAR ENDED DECEMBER 31, 2019.QUARTERLY GAAP EARNINGS PER SHARE $0.12.QUARTERLY CORE EARNINGS PER SHARE $0.23.GAAP BOOK VALUE WAS $14.00 PER COMMON SHARE AT DECEMBER 31, 2019 AS COMPARED TO $14.02 PER COMMON SHARE AT DECEMBER 31, 2018.MANAGEMENT ANTICIPATES CO WILL DECLARE CASH DIVIDEND OF $0.275 PER SHARE ON ITS COMMON STOCK FOR Q1 OF 2020.$0.275 PER SHARE DIVIDEND FOR Q1 2020 WOULD BE A 37.5% INCREASE OVER Q1 OF 2019 DIVIDEND OF $0.20 PER SHARE.
|
EXANTAS CAPITAL CORP REPORTS QUARTERLY GAAP EARNINGS PER SHARE $0.12
|
XAN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-13 22:30:00
| null |
EXANTAS CAPITAL CORP. PRESENTS AT JMP SECURITIES: FINANCIAL SERVICES CONFERENCE, NOV-14-2019 10:30 AM. VENUE: THE ST. REGIS NEW YORK, 2 EAST 55TH STREET, NEW YORK, NEW YORK, UNITED STATES. SPEAKERS: ROBERT C. LIEBER, CHIEF EXECUTIVE OFFICER.
|
EXANTAS CAPITAL CORP. PRESENTS AT JMP SECURITIES: FINANCIAL SERVICES CONFERENCE, NOV-14-2019 10:30 AM
|
XAN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-30 20:30:00
| null |
. REPORTS RESULTS FOR THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2019.Q3 GAAP EARNINGS PER SHARE $0.31.Q3 CORE EARNINGS PER SHARE $0.31.GAAP BOOK VALUE WAS $14.12 PER COMMON SHARE AT SEPT. 30, 2019, UP FROM $14.06 PER COMMON SHARE AT JUNE 30, 2019.EXANTAS CAPITAL - MANAGEMENT ANTICIPATES CO TO DECLARE CASH DIVIDEND OF $0.275 PER SHARE ON COMMON STOCK FOR Q4 OF 2019, WHICH WOULD BE 10.0% INCREASE.QTRLY NET INTEREST INCOME OF $16.6 MILLION VERSUS $14.5 MILLION.
|
EXANTAS CAPITAL POSTS Q3 EPS OF $0.31
|
XAN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-29 22:30:00
| null |
THE MANAGEMENT OF EXANTAS CAPITAL CORP. ANTICIPATES THE COMPANY WILL DECLARE A CASH DIVIDEND OF $0.275 PER SHARE ON ITS COMMON STOCK FOR THE FOURTH QUARTER OF 2019, WHICH WOULD BE A 10.0% INCREASE OVER THE THIRD QUARTER OF 2019 DIVIDEND OF $0.25 PER SHARE AND A 57.1% INCREASE OVER THE FOURTH QUARTER OF 2018 DIVIDEND OF $0.175 PER SHARE.
|
EXANTAS CAPITAL CORP. ANTICIPATES TO DECLARE CASH DIVIDEND FOR THE FOURTH QUARTER OF 2019
|
XAN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-15 22:30:00
| null |
EXANTAS CAPITAL CORP., Q3 2019 EARNINGS CALL, OCT 31, 2019
|
EXANTAS CAPITAL CORP., Q3 2019 EARNINGS CALL, OCT 31, 2019
|
XAN
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-08-06 09:30:00
| null |
GOLDMONEY INC. REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2021.GOLDMONEY INC - QTRLY EARNINGS PER SHARE C$0.08.GOLDMONEY - QTRLY IFRS REVENUE OF C$173.5 MILLION, INCREASE OF C$114.4 MILLION, OR 193%.
|
GOLDMONEY POSTS QUARTERLY EARNINGS PER SHARE C$0.08
|
XAU.TO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-07-13 11:30:00
| null |
GOLDMONEY INC. ANNOUNCES ISSUER BID.GOLDMONEY INC - INTENDS TO REPURCHASE FOR CANCELLATION A TOTAL OF 3 MILLION SHARES AT $2.00 PER SHARE.GOLDMONEY INC - TO REPURCHASE SHARES FROM ROY SEBAG, AN EXECUTIVE OFFICER AND DIRECTOR OF CO.GOLDMONEY INC - SEBAG IS SELLING SHARES TO FACILITATE SETTLEMENT OF MATRIMONIAL MATTERS & NOT RECEIVING ANY PROCEEDS.
|
GOLDMONEY INTENDS TO REPURCHASE FOR CANCELLATION A TOTAL OF 3 MILLION SHARES AT $2.00 PER SHARE
|
XAU.TO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-29 09:30:00
| null |
. REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FISCAL YEAR 2020 AND PUBLISHES ANNUAL LETTER TO SHAREHOLDERS.Q4 REVENUE ROSE 156 PERCENT TO C$164.4 MILLION.
|
GOLDMONEY REPORTS RESULTS FOR FOURTH QUARTER
|
XAU.TO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-02-14 21:30:00
| null |
GOLDMONEY INC. REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2020.GOLDMONEY INC - QTRLY IFRS REVENUE OF C$108.1 MILLION, AN INCREASE OF C$24.1 MILLION (29%) YEAR-OVER-YEAR.
|
GOLDMONEY REPORTS QTRLY IFRS REVENUE OF C$108.1 MILLION
|
XAU.TO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-08 18:30:00
| null |
GOLDMONEY INC. REPORTS RECORD REVENUE FOR SECOND QUARTER 2020, INCREASES QUARTERLY DIVIDEND BY APPROXIMATELY 20%.GOLDMONEY INC QTRLY EARNINGS PER SHARE $0.01.GOLDMONEY INC - QUARTERLY REVENUE OF $127.2 MILLION, AN INCREASE OF $57.6 MILLION (83%) YEAR-OVER-YEAR.
|
GOLDMONEY REPORTS QTRLY EARNINGS PER SHARE $0.01
|
XAU.TO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-05 08:45:00
| null |
LIVE MODERATED VIDEO WEBCAST ON WEDNESDAY, JULY 12TH AT 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / JULY 5, 2023 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT ONCOLOGY INDICATIONS, TODAY ANNOUNCED THAT JEFFREY EISENBERG, CHIEF EXECUTIVE OFFICER AND CURTIS A. LOCKSHIN, PHD, CHIEF SCIENTIFIC OFFICER OF XENETIC BIOSCIENCES WILL PARTICIPATE IN THE VIRTUAL INVESTOR SUMMER SPOTLIGHT SERIES ON WEDNESDAY, JULY 12, 2023 AT 10:00 AM ET.
|
XENETIC BIOSCIENCES, INC. TO PARTICIPATE IN THE VIRTUAL INVESTOR SUMMER SPOTLIGHT SERIES
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-12 12:30:00
| null |
FRAMINGHAM, MA / ACCESSWIRE / MAY 12, 2023 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT CANCERS, TODAY ANNOUNCED IT WILL EFFECT A ONE-FOR-TEN REVERSE STOCK SPLIT OF ITS AUTHORIZED, ISSUED AND OUTSTANDING COMMON STOCK. PURSUANT TO THE CERTIFICATE OF CHANGE FILED WITH THE SECRETARY OF STATE OF THE STATE OF NEVADA, THE REVERSE STOCK SPLIT WILL BE EFFECTIVE AT 12:01 A.M.
|
XENETIC BIOSCIENCES, INC. ANNOUNCES REVERSE STOCK SPLIT OF COMMON STOCK
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-11 16:30:00
| null |
- CONTINUED PROGRESS WITH THE DNASE-BASED ONCOLOGY PROGRAM TOWARDS PHASE 1 STUDY FOR THE TREATMENT OF PANCREATIC CARCINOMA AND OTHER LOCALLY ADVANCED OR METASTATIC SOLID TUMORS - ENDED THE QUARTER WITH $12.0 MILLION OF CASH TO FUND OPERATIONS AND DRIVE PIPELINE FORWARD FRAMINGHAM, MA / ACCESSWIRE / MAY 11, 2023 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT CANCERS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2023 AND PROVIDED A BUSINESS UPDATE. "WE MADE SOLID PROGRESS WITH OUR DNASE PLATFORM BY THE ESTABLISHMENT OF A RESEARCH AND DEVELOPMENT COLLABORATION WITH THE SCRIPPS RESEARCH INSTITUTE.
|
XENETIC BIOSCIENCES, INC. REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-04 08:35:00
| null |
DR. BISSONNETTE BRINGS OVER 25 YEARS IN SMALL MOLECULE AND BIOTHERAPEUTIC DRUG DISCOVERY AND DEVELOPMENT, ONCOLOGY AND INFLAMMATION RESEARCH AND REGULATORY EXPERTISE FRAMINGHAM, MA / ACCESSWIRE / MAY 4, 2023 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT CANCERS, TODAY ANNOUNCED IT HAS ENGAGED REID P. BISSONNETTE, PH.D.
|
XENETIC BIOSCIENCES, INC. BOLSTERS R&D AND REGULATORY EXPERTISE WITH APPOINTMENT OF REID P. BISSONNETTE, PH.D.
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-03 08:35:00
| null |
MR. CULLISON BRINGS OVER 20 YEARS OF EXPERIENCE IN THE PHARMACEUTICAL INDUSTRY WITH A BROAD RANGE OF EXPERTISE ACROSS BUSINESS DEVELOPMENT AND STRATEGIC PLANNING FRAMINGHAM, MA / ACCESSWIRE / MAY 3, 2023 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT CANCERS, TODAY ANNOUNCED IT HAS ENGAGED SCOTT N. CULLISON TO SERVE AS AN EXECUTIVE CONSULTANT FOR BUSINESS DEVELOPMENT AND TO SUPPORT THE ADVANCEMENT OF THE COMPANY'S DNASE-BASED ONCOLOGY PLATFORM.
|
XENETIC BIOSCIENCES, INC. ADDS BUSINESS DEVELOPMENT EXPERTISE WITH APPOINTMENT OF SCOTT N. CULLISON
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-11 08:30:00
| null |
- COLLABORATION PROVIDES A SIGNIFICANT STEP FORWARD IN THE ADVANCEMENT OF XENETIC'S DNASE-BASED ONCOLOGY PROGRAM TOWARDS PHASE 1 CLINICAL DEVELOPMENT - SYSTEMIC DNASE PROGRAM INITIALLY TARGETING MULTI-BILLION-DOLLAR INDICATIONS INCLUDING PANCREATIC CARCINOMA FRAMINGHAM, MA / ACCESSWIRE / APRIL 11, 2023 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT CANCERS, TODAY ANNOUNCED IT HAS ENTERED INTO A RESEARCH FUNDING AND OPTION AGREEMENT (THE "AGREEMENT") WITH THE SCRIPPS RESEARCH INSTITUTE ("TSRI") TO ADVANCE THE DEVELOPMENT OF THE COMPANY'S SYSTEMIC DNASE PROGRAM AS WELL AS ITS DNASE-ARMORED CAR T PROGRAM. THE SYSTEMIC DNASE PROGRAM IS EXPECTED TO BE EVALUATED IN COMBINATION WITH EXISTING THERAPIES FOR THE POTENTIAL TREATMENT OF PANCREATIC CARCINOMA AND OTHER SOLID TUMOR INDICATIONS.
|
XENETIC BIOSCIENCES, INC. ANNOUNCES RESEARCH AND DEVELOPMENT COLLABORATION WITH THE SCRIPPS RESEARCH INSTITUTE TO ADVANCE DNASE PLATFORM
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-23 07:35:00
| null |
- YEAR MARKED BY TRANSFORMATIONAL STRATEGIC LICENSE OF THE DNASE ONCOLOGY PLATFORM AND SHIFT IN FOCUS TO TREATMENT OF LOCALLY ADVANCED OR METASTATIC SOLID TUMORS - DNASE PROGRAM PROGRESSING TOWARDS PHASE 1 CLINICAL DEVELOPMENT - CLOSED THE YEAR WITH $13.1 MILLION OF CASH EXPECTED TO FUND OPERATIONS AND DRIVE PIPELINE DEVELOPMENT FRAMINGHAM, MA / ACCESSWIRE / MARCH 23, 2023 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT CANCERS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FULL YEAR 2022 AND PROVIDED A BUSINESS UPDATE. "2022 REPRESENTED A TRANSFORMATIONAL YEAR FOR THE COMPANY.
|
XENETIC BIOSCIENCES, INC. REPORTS FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-16 11:00:00
| null |
- LIVE MODERATED VIDEO WEBCAST WITH MEMBERS OF THE XENETIC LEADERSHIP TEAM AND RECOGNIZED ONCOLOGY LEADER AND NETS RESEARCHER, JONATHAN SPICER, MD, PHD ON WEDNESDAY, MARCH 29TH AT 11:00 AM ET - FRENCHTOWN, NJ / ACCESSWIRE / MARCH 16, 2023 / JTC TEAM ("JTC"), A FULLY INTEGRATED CORPORATE COMMUNICATIONS AND INVESTOR RELATIONS FIRM, TODAY ANNOUNCED IT WILL HOST THE VIRTUAL INVESTOR NETS IN CANCER SPOTLIGHT EVENT FEATURING XENETIC BIOSCIENCES ON WEDNESDAY, MARCH 29, 2023, AT 11:00 AM ET. ACCESS THE EVENT HERE.
|
JTC TEAM TO HOST VIRTUAL INVESTOR NETS IN CANCER SPOTLIGHT EVENT FEATURING XENETIC BIOSCIENCES
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-17 08:05:00
| null |
FRAMINGHAM, MA / ACCESSWIRE / JANUARY 17, 2023 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT ONCOLOGY INDICATIONS, TODAY ANNOUNCED THAT THE CANADIAN INTELLECTUAL PROPERTY OFFICE (CIPO) HAS ISSUED A NOTICE OF ALLOWANCE FOR PATENT APPLICATION NO. 3,001,543 TITLED, "METHOD TO IMPROVE SAFETY AND EFFICACY OF ANTI-CANCER THERAPY.
|
XENETIC BIOSCIENCES, INC. ANNOUNCES NOTICE OF ALLOWANCE FOR CANADIAN PATENT COVERING USE OF DNASE ENZYME FOR PREVENTING OR AMELIORATING TOXICITY ASSOCIATED WITH CHEMOTHERAPY
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-16 08:35:00
| null |
APPOINTMENT OF DR. SPICER TO SCIENTIFIC ADVISORY BOARD BOLSTERS EXPERTISE IN NEUTROPHIL EXTRACELLULAR TRAPS ("NETS") IN CANCER BIOLOGY AND PROVIDES VALUABLE ASSISTANCE IN ADVANCING DEVELOPMENT OF THE COMPANY'S DNASE PLATFORM FRAMINGHAM, MA / ACCESSWIRE / NOVEMBER 16, 2022 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT ONCOLOGY INDICATIONS, TODAY ANNOUNCED THE APPOINTMENT OF JONATHAN SPICER, MD, PHD TO ITS SCIENTIFIC ADVISORY BOARD ("SAB"). DR. SPICER IS RECOGNIZED AS A LEADER IN UNDERSTANDING HOW NEUTROPHILS IMPACT CANCER PROGRESSION, IN PARTICULAR, THE ROLE OF NETS IN CANCER BIOLOGY, AND HAS DEVELOPED ONE OF THE MOST ACTIVE RESEARCH PROGRAMS IN THE AREA OF NEOADJUVANT IMMUNOTHERAPY FOR OPERABLE LUNG CANCER.
|
XENETIC BIOSCIENCES, INC. ENGAGES LEADING NETS RESEARCH EXPERT, JONATHAN SPICER, MD, PHD FOR ADVANCEMENT OF DNASE ONCOLOGY PLATFORM
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-10 07:05:00
| null |
- CONTINUED ADVANCEMENT OF LEAD TECHNOLOGY, DNASE-BASED ONCOLOGY PLATFORM, IN LOCALLY ADVANCED OR METASTATIC SOLID TUMORS TOWARDS PHASE 1 CLINICAL DEVELOPMENT - ENDED THE QUARTER WITH $13.8 MILLION OF CASH EXPECTED TO FUND OPERATIONS AND DRIVE EXPANDED PIPELINE DEVELOPMENT FORWARD FRAMINGHAM, MA / ACCESSWIRE / NOVEMBER 10, 2022 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT ONCOLOGY INDICATIONS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2022 AND PROVIDED A BUSINESS UPDATE. "WE HAVE CONTINUED TO MAKE ENCOURAGING PROGRESS WITH OUR RECENTLY IN-LICENSED DNASE-BASED ONCOLOGY ASSET OVER THE COURSE OF THE PAST QUARTER AND ARE EXCITED ABOUT THE POTENTIAL OF THIS PLATFORM TECHNOLOGY," COMMENTED JEFFREY EISENBERG, CHIEF EXECUTIVE OFFICER OF XENETIC.
|
XENETIC BIOSCIENCES, INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-11 08:05:00
| null |
SIGNING OF PATENT ASSIGNMENT FROM CLS THERAPEUTICS AS PART OF A COLLABORATION AGREEMENT WITH VOLITION AND CLS THERAPEUTICS TO DEVELOP NETS-TARGETED ADOPTIVE CELL THERAPIES FOR THE TREATMENT OF CANCER FRAMINGHAM, MA / ACCESSWIRE / OCTOBER 11, 2022 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES FOR THE TREATMENT OF HARD TO TREAT CANCERS, TODAY ANNOUNCED THE SIGNING OF A PATENT ASSIGNMENT FROM CLS THERAPEUTICS, INC. ("CLS") TO XENETIC RELATED TO XENETIC'S PREVIOUSLY ANNOUNCED COLLABORATION WITH VOLITIONRX LIMITED (NYSE AMERICAN:VNRX) ("VOLITION"), A MULTI-NATIONAL EPIGENETICS COMPANY, AND CLS, A BIOPHARMACEUTICAL COMPANY DEVELOPING FIRST-IN-CLASS THERAPIES BASED ON THE DISCOVERY OF NOVEL THERAPEUTIC TARGETS. IN CONSIDERATION OF THE PATENT ASSIGNMENT, XENETIC WILL ALSO ISSUE 850,000 SHARES OF COMMON STOCK TO CLS.
|
XENETIC BIOSCIENCES, INC. ANNOUNCES SIGNING OF PATENT ASSIGNMENT RELATED TO COLLABORATION WITH VOLITIONRX LIMITED AND CLS THERAPEUTICS
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-04 08:00:00
| null |
FRAMINGHAM, MA / ACCESSWIRE / OCTOBER 4, 2022 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT CANCERS, TODAY ANNOUNCED THE APPOINTMENT OF ALLAN TSUNG, MD TO ITS SCIENTIFIC ADVISORY BOARD. DR. TSUNG IS A NATIONALLY AND INTERNATIONALLY RECOGNIZED LEADER SPECIALIZING IN EVALUATING AND CARING FOR PATIENTS WITH LIVER, BILE DUCT AND PANCREAS CANCERS AND IS AN EXPERT IN LAPAROSCOPIC AND ROBOTIC SURGERY.
|
XENETIC BIOSCIENCES, INC. APPOINTS GLOBALLY RECOGNIZED ONCOLOGY LEADER, ALLAN TSUNG, MD TO ITS SCIENTIFIC ADVISORY BOARD
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-12 08:00:00
| null |
SECOND QUARTER MARKED BY DEAL TO IN-LICENSE DNASE-BASED ONCOLOGY PLATFORM WHICH EXPANDS PIPELINE WITH WELL-DEFINED AND ACCELERATED PATH TO CLINIC ADVANCING LEAD DNASE PROGRAM TOWARDS PHASE 1 STUDY FOR THE TREATMENT OF PANCREATIC CARCINOMA AND OTHER LOCALLY ADVANCED OR METASTATIC SOLID TUMORS ENDED THE QUARTER WITH $14.9 MILLION OF CASH TO FUND OPERATIONS AND DRIVE EXPANDED PIPELINE DEVELOPMENT FORWARD FRAMINGHAM, MA / ACCESSWIRE / AUGUST 12, 2022 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT ONCOLOGY INDICATIONS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2022 AND PROVIDED A BUSINESS UPDATE. "THE PAST QUARTER WAS MARKED BY A SHIFT IN OUR FOCUS AND PRIORITIZATION OF OUR PIPELINE WITH THE IN-LICENSING OF OUR DNASE-BASED ONCOLOGY PLATFORM.
|
XENETIC BIOSCIENCES, INC. REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-02 08:05:00
| null |
FRAMINGHAM, MA / ACCESSWIRE / AUGUST 2, 2022 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD-TO-TREAT CANCERS, AND VOLITIONRX LIMITED (NYSE AMERICAN:VNRX) ("VOLITION"), A MULTI-NATIONAL EPIGENETICS COMPANY, TODAY ANNOUNCED A RESEARCH AND DEVELOPMENT COLLABORATION TO DEVELOP NEUTROPHIL EXTRACELLULAR TRAPS ("NETS") TARGETED, ADOPTIVE CELL THERAPIES FOR THE TREATMENT OF CANCER. THE COLLABORATION IS AN EARLY EXPLORATORY PROGRAM TO EVALUATE THE POTENTIAL COMBINATION OF VOLITION'S NU.Q® NETS TEST AND XENETIC'S DNASE-ARMORED CAR T PLATFORM TO DEVELOP PROPRIETARY ADOPTIVE CELL THERAPIES POTENTIALLY TARGETING MULTIPLE TYPES OF SOLID CANCERS.
|
XENETIC BIOSCIENCES, INC. AND VOLITIONRX LIMITED COLLABORATE TO DEVELOP NETS-TARGETED ADOPTIVE CELL THERAPIES FOR THE TREATMENT OF CANCER
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-07 09:00:00
| null |
DNASE-BASED ONCOLOGY PLATFORM HAS THE POTENTIAL TO IMPROVE OUTCOMES OF EXISTING THERAPEUTIC AGENTS IN MULTIPLE SOLID TUMOR INDICATIONS SYSTEMIC DNASE PROGRAM INITIALLY TARGETING MULTI-BILLION-DOLLAR INDICATIONS INCLUDING PANCREATIC CARCINOMA FRAMINGHAM, MA / ACCESSWIRE / JULY 7, 2022 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD-TO-TREAT CANCERS, TODAY ANNOUNCED IT HAS ENTERED INTO A MANUFACTURING AGREEMENT WITH CATALENT PHARMA SOLUTIONS LLC ("CATALENT"), WHICH WILL INCLUDE CGMP MANUFACTURING FOR THE COMPANY'S RECOMBINANT PROTEIN, HUMAN DNASE I. CATALENT IS THE GLOBAL LEADER IN ENABLING BIOPHARMA, CELL, GENE, AND CONSUMER HEALTH PARTNERS TO OPTIMIZE DEVELOPMENT, LAUNCH, AND SUPPLY OF BETTER PATIENT TREATMENTS ACROSS MULTIPLE MODALITIES.
|
XENETIC BIOSCIENCES, INC. ENGAGES CATALENT FOR CLINICAL MANUFACTURING TO ADVANCE DNASE-BASED ONCOLOGY PLATFORM TOWARDS PHASE 1 STUDY
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-02 14:00:00
| null |
- LIVE VIDEO WEBCAST WITH MODERATED ROUNDTABLE WITH MEMBERS OF THE XENETIC LEADERSHIP TEAM AND SURGICAL ONCOLOGY KEY OPINION LEADER, ALLAN TSUNG, MD ON THURSDAY, JUNE 9TH AT 11:00 AM ET - FRENCHTOWN, NJ / ACCESSWIRE / JUNE 2, 2022 / JTC TEAM ("JTC"), A FULLY INTEGRATED CORPORATE COMMUNICATIONS AND INVESTOR RELATIONS FIRM, TODAY ANNOUNCED IT WILL HOST THE VIRTUAL INVESTOR INNOVATION IN ONCOLOGY EVENT FEATURING XENETIC BIOSCIENCES ON THURSDAY, JUNE 9, 2022 AT 11:00 AM ET. ACCESS THE EVENT HERE.
|
JTC TEAM TO HOST VIRTUAL INVESTOR INNOVATION IN ONCOLOGY FEATURING XENETIC BIOSCIENCES
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-02 08:35:00
| null |
LIVE VIDEO WEBCAST WITH MODERATED ROUNDTABLE WITH MEMBERS OF THE XENETIC LEADERSHIP TEAM AND SURGICAL ONCOLOGY KEY OPINION LEADER, ALLAN TSUNG, MD ON THURSDAY, JUNE 9TH AT 11:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / JUNE 2, 2022 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES FOR THE TREATMENT OF HARD TO TREAT CANCERS, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE VIRTUAL INVESTOR INNOVATION IN ONCOLOGY EVENT ON THURSDAY, JUNE 9, 2022 AT 11:00 AM ET. FOR THE ROUNDTABLE DISCUSSION, JEFFREY F.
|
XENETIC BIOSCIENCES, INC. TO PARTICIPATE IN THE VIRTUAL INVESTOR INNOVATION IN ONCOLOGY EVENT
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-12 16:05:00
| null |
- COMPANY COMPLETED RECENT TRANSACTION TO EXPAND ONCOLOGY PIPELINE WITH IN-LICENSING OF DNASE BASED PLATFORM COMPRISING MULTIPLE THERAPEUTIC MODALITIES - DNASE BASED ONCOLOGY PLATFORM HAS THE POTENTIAL TO IMPROVE OUTCOMES OF EXISTING THERAPEUTIC AGENTS IN MULTIPLE SOLID TUMOR INDICATIONS - FOCUSING RESOURCES ON ADVANCING DNASE BASED ONCOLOGY PLATFORM IN LOCALLY ADVANCED OR METASTATIC SOLID TUMORS TOWARDS PHASE 1 CLINICAL DEVELOPMENT - ENDED THE QUARTER WITH $16.2 MILLION OF CASH TO FUND OPERATIONS AND DRIVE PIPELINE FORWARD FRAMINGHAM, MA / ACCESSWIRE / MAY 12, 2022 / XENETIC BIOSCIENCES, INC. (NASDAQ:XBIO) ("XENETIC" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE IMMUNE-ONCOLOGY TECHNOLOGIES ADDRESSING HARD TO TREAT ONCOLOGY INDICATIONS, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2022 AND PROVIDED A BUSINESS UPDATE. "OUR STRATEGIC FOCUS THROUGHOUT THE FIRST QUARTER WAS WORKING TOWARDS THE COMPLETION OF OUR EXCLUSIVE LICENSE AGREEMENT WITH CLS THERAPEUTICS ("CLS") TO DEVELOP ITS INTERVENTIONAL DNASE BASED ONCOLOGY PLATFORM.
|
XENETIC BIOSCIENCES, INC. REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
|
XBIO
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.